In the present study, we evaluated the efficacies of FOXM1 selective small molecule inhibitors alone or in combination with first-line chemotherapy on SCLC progression, including chemotherapeutic resistance using SCLC xenografts and spontaneous models. This evidence concerns the gene FOXM1 and small cell lung carcinoma.